JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

13.8

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.77

Max

13.86

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.8B

14B

Pardavimai

392M

85B

P/E

Sektoriaus vid.

17.909

34.393

Dividendų pajamingumas

0.66

Pelno marža

16.496

Darbuotojai

27,811

EBITDA

-622M

25B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+17.39% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.66%

2.54%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-476M

12B

Ankstesnė atidarymo kaina

13.8

Ankstesnė uždarymo kaina

13.8

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-23 17:49; UTC

Uždarbis

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

2025-07-23 17:48; UTC

Uždarbis

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

2025-07-23 17:48; UTC

Uždarbis

Dr Reddy's Labs 1Q Rev $85.45B >RDY

2025-05-09 18:56; UTC

Uždarbis

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

2025-05-09 18:56; UTC

Uždarbis

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

2025-01-23 17:46; UTC

Uždarbis

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

2025-01-23 17:42; UTC

Uždarbis

Dr. Reddy's 3Q Rev INR83.59B

2024-11-05 11:01; UTC

Uždarbis

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

2024-11-05 11:00; UTC

Uždarbis

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

2024-11-05 10:57; UTC

Uždarbis

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

2024-11-05 10:57; UTC

Uždarbis

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

Akcijų palyginimas

Kainos pokytis

Dr Reddy's Laboratories Ltd-ADR Prognozė

Kainos tikslas

By TipRanks

17.39% į viršų

12 mėnesių prognozė

Vidutinis 16.2 USD  17.39%

Aukščiausias 16.9 USD

Žemiausias 15.5 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Dr Reddy's Laboratories Ltd-ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 13.84Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.